Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AOP-P1
- Development stage
- Unknown
- Lead developer
- First Affiliated Hospital of Kunming Medical University
- Modality
- Peptides
- Administration
- Topical
01
Overview
AOP-P1 is a natural bioactive peptide currently under clinical investigation for the treatment of melasma. Developed by the First Affiliated Hospital of Kunming Medical University, the drug is formulated as a topical solution, typically dissolved in a 20% propylene glycol vehicle. AOP-P1 is characterized as an antioxidant peptide (AOP) that aims to mitigate hyperpigmentation by addressing oxidative stress and potentially modulating melanogenesis pathways. It is being evaluated in parallel-group, split-face interventional studies to determine its safety, tolerability, and cosmetic efficacy in reducing the severity of melasma in women.
- Other names
- natural peptide AOP-P1
Beyond the preview
Go deeper on AOP-P1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AOP-P1.